Related Experiment Video
Updated: Jul 16, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Exploring the Impact of Multiple Gene Mutations on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Rui Jing1, Yandong Miao2, Ummi Nadira Daut3
1Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, UPM Serdang, Selangor Darul Ehsan 43400, Malaysia.
Abstract:
Nonsmall cell lung cancer (NSCLC) is characterized by diverse genetic alterations, among which epidermal growth factor receptor (EGFR) mutations are the most common, particularly in adenocarcinoma, occurring in 10-15% of patients. However, in Asian populations, the EGFR mutation rate can be as high as 51.4%. Other mutations such as Kirsten rat sarcoma viral oncogene (KRAS), anaplastic lymphoma kinase, rearranged during transfection, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, human EGFR 2 (HER2), V-Raf murine sarcoma viral oncogene homologue B (BRAF), mesenchymal-epithelial transition, and c-ros oncogene 1 (ROS1) are also frequently observed. EGFR mutations may co-occur with these alterations, influencing response to targeted therapy. The advent of EGFR tyrosine kinase inhibitors (TKI) (EGFR-TKIs) has markedly improved treatment outcomes in EGFR-mutant NSCLC. However, approximately 20%-30% of patients still develop primary or acquired resistance to EGFR-TKIs. Emerging evidence suggests that concurrent gene mutations contribute significantly to this resistance. Therefore, different EGFR subtypes and coexisting mutations may affect TKI efficacy. This review highlights the mutation spectrum of Asian NSCLC patients, particularly focusing on concurrent mutations and their impact on EGFR-TKI response. We also discuss evolving treatment strategies and summarize ongoing clinical trials targeting comutation scenarios. These insights may help guide personalized therapy decisions and provide directions for future research.
Insights
Epidermal growth factor receptor (EGFR) mutations are common in nonsmall cell lung cancer (NSCLC), especially in Asian populations. Concurrent mutations significantly impact EGFR tyrosine kinase inhibitor (TKI) efficacy and resistance, guiding personalized NSCLC therapy.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Nonsmall cell lung cancer (NSCLC) exhibits diverse genetic alterations, with epidermal growth factor receptor (EGFR) mutations being most prevalent, particularly in adenocarcinomas.
- EGFR mutation rates are notably higher in Asian populations (up to 51.4%).
- Other common mutations include KRAS, ALK, PIK3CA, HER2, BRAF, MET, and ROS1, which can co-occur with EGFR mutations.
Purpose of the Study:
- To review the mutation spectrum in Asian NSCLC patients, focusing on concurrent mutations.
- To analyze the impact of these coexisting mutations on the response to EGFR tyrosine kinase inhibitors (TKIs).
- To discuss evolving treatment strategies and clinical trials for NSCLC with comutations.
Main Methods:
- Literature review and synthesis of existing research on NSCLC genetics and targeted therapies.
- Analysis of mutation data, focusing on EGFR and common co-occurring mutations in Asian populations.
- Examination of the influence of comutations on EGFR-TKI efficacy and resistance mechanisms.
Main Results:
- EGFR mutations are a key driver in NSCLC, with significant prevalence in Asian patients.
- Concurrent mutations significantly affect patient response to EGFR-TKIs, contributing to primary and acquired resistance in 20-30% of cases.
- Different EGFR subtypes and specific comutations influence TKI effectiveness.
Conclusions:
- Understanding the spectrum of concurrent mutations in Asian NSCLC patients is crucial for predicting EGFR-TKI response.
- Personalized therapy strategies must consider these comutations to optimize treatment outcomes.
- Further research and clinical trials are needed to address treatment challenges posed by comutations in NSCLC.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...